MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
13.90
+0.56
+4.20%
Pre Market: 14.50 +0.6 +4.32% 05:16 04/15 EDT
OPEN
13.56
PREV CLOSE
13.34
HIGH
14.07
LOW
13.15
VOLUME
35
TURNOVER
0
52 WEEK HIGH
20.72
52 WEEK LOW
3.390
MARKET CAP
371.33M
P/E (TTM)
-2.3809
1D
5D
1M
3M
1Y
5Y
1D
Avalo Therapeutics Price Target Maintained With a $40.00/Share by BTIG
Dow Jones · 1d ago
BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target
Benzinga · 1d ago
Weekly Report: what happened at AVTX last week (0406-0410)?
Weekly Report · 2d ago
Avalo Therapeutics announces annual shareholder meeting via virtual webcast
Reuters · 4d ago
Avalo CMO Doyle Mittie disposes 3,970 shares worth $71,511
Reuters · 6d ago
Avalo Therapeutics initiated with an Outperform at Wolfe Research
TipRanks · 6d ago
Citizens Initiates Coverage of Avalo Therapeutics (AVTX) with Market Outperform Recommendation
NASDAQ · 04/07 00:04
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
NASDAQ · 04/06 15:10
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Webull offers Avalo Therapeutics Inc stock information, including NASDAQ: AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.